CardioDx – Bringing molecular diagnostics into the cardiovascular arena

CardioDx completes validation study of first-of-its-kind genomic test for coronary artery disease

CardioDx, a cardiovascular genomic diagnostics company, announced today that the company has successfully completed its multicenter validation study for Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(1) coronary artery disease (CAD) in patients with stable chest pain. The company expects to present results of the study by the end of 2009, and will publish the results in 2010.

CardioDx completes validation study of first-of-its-kind genomic test for coronary artery disease

 
PALO ALTO, Calif., August 25, 2009 – CardioDx, a cardiovascular genomic diagnostics company, announced today that the company has successfully completed its multicenter validation study for Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(1) coronary artery disease (CAD) in patients with stable chest pain. The company expects to present results of the study by the end of 2009, and will publish the results in 2010.